Europe Europe accounts for more than half of Sandoz’s global sales, and the company keeps reinvesting here, from biosimilar development and manufacturing in Slovenvia and France to antibiotic production in Austria. Christophe Delenta, President Europe, explains how closely Sandoz’s success is tied to Europe, how the company plans to grow its…
Europe How can Europe’s mid-sized companies compete with Big Pharma and bring life-changing innovations to patients? The answer, increasingly, is rare diseases. Most rare diseases still have no available treatments, and the majors tend to pass on niche assets with limited potential markets. This is where companies like Angelini, Servier,…
Europe 24 of the top 25 injectable drugs on the market rely on a BD component. This position puts the company at the centre of the GLP-1 boom, the coming biosimilars wave, and the shift of injectable treatment from hospitals to patients’ homes. Patrick Jeukenne, BD’s worldwide president of Pharmaceutical Systems,…
USA The American pharmaceutical market dominates the global landscape, accounting for nearly 50 percent of all global prescription drug sales by value. In 2024, the US market alone generated roughly USD 800 billion of the USD 1.7 trillion worldwide pharmaceutical revenue, cementing its status as the undisputed epicentre of the global…
Europ Angelini Pharma’s transition from a predominantly European pharmaceutical business to a global player in both brain health and rare neurological diseases represents a significant shift in strategy and ambition. CEO Sergio Marullo di Condojanni examines how the acquisition of Catalyst accelerates this transformation, the challenges of sustaining pharmaceutical innovation in…
Italy Our differentiation is based on the quality of our products, our scientific expertise and our approach to the market For Dompé, international growth is not simply a question of entering new markets, but of extending the scientific expertise, manufacturing capabilities and entrepreneurial vision that have shaped its business for generations.…
Korea Brad Edwards became the first foreign general manager in the Lundbeck Korea’s 23-year history last year, joining from a background at Shire and Takeda across Australia and Singapore. He spoke to us about steering the company’s shift from psychiatry toward neuro-rare disease, the upcoming launch of its new migraine treatment,…
Europe Behind every dose of heparin lies a complex industrial process in which access to raw materials, traceability and manufacturing expertise are as important as the medicine itself. Luis Solera, CEO of Bioiberica, examines how the Barcelona-based group has turned these capabilities into a global business spanning human, animal and plant…
France We need to raise our voice and say: look at us too, there are also mid-sized pharma companies out there looking for something different In conversation at BIO 2026 in San Diego, Frédéric Scaerou, Head of Global Business Development at Servier, explains why the company is staying disciplined rather than…
Europe Michala Fischer-Hansen, EVP and Head of Europe & International Markets at Lundbeck, discusses her return to pharma and Lundbeck’s focused innovator strategy, centred on neuroscience, R&D and growth through regional partnerships. She examines Europe’s evolving pharmaceutical landscape, from patent expiries and pricing pressure to growing attention on brain health, and…
Germany DACH should become a powerhouse for the Group Germany is emerging as a key growth and launch market for Ipsen, with the DACH region now ranking as the Group’s leading European affiliate and gaining momentum across Oncology, Rare Disease and Neuroscience. As Ipsen enters its next phase of growth, new…
Europe ESTEVE has successfully reshaped itself in the recent years as an integrated healthcare company with two distinct growth engines: highly specialised pharmaceuticals and a global small-molecule CDMO platform, united by a shared purpose, long-term vision and a commitment to improving patients’ lives. As the US grows in relevance and investment…
See our Cookie Privacy Policy Here